ESMO 2023 Prostate Cancer

Viewing 1-20 of 66 articles

ESMO 2023: Delineating Staging Pelvic Lymph Node Dissection Before Radiotherapy and Positioning Primary Prostatectomy

ESMO 2023: How Much Systemic Treatment Is Needed and How Long?

ESMO 2023: Dose Intensification and Field Expansion of External Beam Radiation Therapy

ESMO 2023: Tolerance and Long-Term Side-Effects

ESMO 2023: Usefulness and Limitations of PSMA Imaging/PET in High-Risk Localized Disease

ESMO 2023: Patient-Reported Outcomes in Men with mCRPC and HRR Mutations Receiving Talazoparib + Enzalutamide vs Placebo + Enzalutamide: Results from the Phase 3 TALAPRO-2 Study

ESMO 2023: Application of Novel Machine Learning Model in 68Ga-PSMA-11 PET/CT – Predicting Survival in Oligometastatic Prostate Cancer Patients

ESMO 2023: APEX-01: First-in-Human Phase 1/2 Study of ARX517, an Anti-PSMA ADC, in Patients with mCRPC

ESMO 2023: Impact of Intensified Androgen Deprivation Therapy in the Metastatic Castration-Sensitive Prostate Cancer Setting on Metastatic Castration-Resistant Prostate Cancer Disease Characteristics and Survival Outcomes

ESMO 2023: How to Best Integrate Biology

ESMO 2023: Talazoparib plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Subgroup Analyses of the All-Comers Cohort from TALAPRO-2 by HRR Status

ESMO 2023: Exploration of Germline vs Somatic Origin of Homologous Recombination Repair Gene Alterations and Potential Associations with Anti-Tumor Activity in the HRR-Deficient Population from TALAPRO-2

ESMO 2023: Real World Treatment Patterns of Metastatic Prostate Cancer with Enhanced Access to Homologous Recombination Repair Genomic Testing and PARP Inhibitors

ESMO 2023: Efficacy of Niraparib and Abiraterone Acetate + Prednisone in Homologous Recombination Repair Gene-Altered Metastatic Castration-Resistant Prostate Cancer by Tissue And/or Plasma Assays in the MAGNITUDE Trial

ESMO 2023: PSMAfore Discussant: Using Clinical Intelligence to Define First Line mCRPC Therapy

ESMO 2023: Next Generation Imaging: How Does It Change the Evidence Seen in Trials?

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer

ESMO 2023: Phase 1/2 Study of Bavdegalutamide, a PROTAC Androgen Receptor Degrader, in mCRPC: Radiographic Progression-Free Survival in Patients with AR Ligand-Binding Domain Mutations

ESMO 2023: Treatment Patterns Among Novel Hormonal Therapy-experienced Patients with mCRPC

ESMO 2023: Exposure-Safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with mCRPC in TALAPRO-2 Trial

1
2
3
4